Epidemiology of non-alcoholic and alcoholic fatty liver diseases
- PMID: 32258520
- PMCID: PMC7063528
- DOI: 10.21037/tgh.2019.09.08
Epidemiology of non-alcoholic and alcoholic fatty liver diseases
Abstract
Liver diseases are fast emerging as global health priorities. Fatty liver is described in the setting of non-alcoholic fatty liver disease (NAFLD) as well as alcoholic liver disease (ALD), the pathogenesis of excess fat being different in the two conditions while both are important components of the changing face of burden of liver diseases worldwide. They are intimately associated with a globalized economy and an increasingly homogenous socio- cultural order with a westernized lifestyle. The accompanying adoption of a progressively sedentary life, consumption of diet dense in calories facilitate development of NAFLD while a spiraling upward trend in alcohol use along with earlier age of drinking as well as increased amount of per capita alcohol consumption increases the prevalence of ALD globally. Adverse health outcomes in NAFLD as well as ALD are caused not only by progressive liver fibrosis that is the most significant factor for liver related and all-cause mortality in both but also by non-liver (cardiovascular, cancer, accidents, neurological) clinical outcomes that calls for a multidisciplinary and social approach to these conditions. We present here an outline of facets of epidemiology of both NAFLD as well as ALD along with its' public health implications. A broad-based integrated approach that incorporates social, behavioral as well as biological targets need to be undertaken at a health system level in a planned manner for these evolving liver health priorities that disproportionately challenges the low- and middle-income countries of Asia, South America and Africa.
Keywords: Lean; obesity; steatosis.
2020 Translational Gastroenterology and Hepatology. All rights reserved.
Conflict of interest statement
Conflicts of Interest: The authors have no conflicts of interest to declare.
Similar articles
-
[Hypothetical Alcohol Consumption Interventions and Hepatic Steatosis: A Longitudinal Study in a Large Cohort].Sichuan Da Xue Xue Bao Yi Xue Ban. 2024 May 20;55(3):653-661. doi: 10.12182/20240560503. Sichuan Da Xue Xue Bao Yi Xue Ban. 2024. PMID: 38948274 Free PMC article. Chinese.
-
Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities.Front Med (Lausanne). 2020 Aug 20;7:448. doi: 10.3389/fmed.2020.00448. eCollection 2020. Front Med (Lausanne). 2020. PMID: 32974366 Free PMC article. Review.
-
Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease.J Hepatol. 2022 Oct;77(4):918-930. doi: 10.1016/j.jhep.2022.04.040. Epub 2022 May 20. J Hepatol. 2022. PMID: 35605744
-
Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry.Clin Gastroenterol Hepatol. 2022 Oct;20(10):2296-2306.e6. doi: 10.1016/j.cgh.2021.11.004. Epub 2021 Nov 9. Clin Gastroenterol Hepatol. 2022. PMID: 34768009
-
Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease.Transl Gastroenterol Hepatol. 2020 Apr 5;5:31. doi: 10.21037/tgh.2019.11.14. eCollection 2020. Transl Gastroenterol Hepatol. 2020. PMID: 32258535 Free PMC article. Review.
Cited by
-
Evaluation of the role of some non-enzymatic antioxidants among Iraqi patients with non-alcoholic fatty liver disease.Open Life Sci. 2024 Jun 27;19(1):20220881. doi: 10.1515/biol-2022-0881. eCollection 2024. Open Life Sci. 2024. PMID: 38947767 Free PMC article.
-
Severe, but not mild to moderate, non-alcoholic fatty liver disease associated with increased risk of subclinical coronary atherosclerosis.BMC Cardiovasc Disord. 2021 May 19;21(1):244. doi: 10.1186/s12872-021-02060-z. BMC Cardiovasc Disord. 2021. PMID: 34011282 Free PMC article.
-
3,5-Dimethyl-2,4,6-trimethoxychalcone Lessens Obesity and MAFLD in Leptin-Deficient ob/ob Mice.Int J Mol Sci. 2024 Sep 11;25(18):9838. doi: 10.3390/ijms25189838. Int J Mol Sci. 2024. PMID: 39337328 Free PMC article.
-
Diabetes Mellitus Increases the Risk of Significant Hepatic Fibrosis in Patients With Non-alcoholic Fatty Liver Disease.J Clin Exp Hepatol. 2022 Mar-Apr;12(2):409-416. doi: 10.1016/j.jceh.2021.07.001. Epub 2021 Jul 9. J Clin Exp Hepatol. 2022. PMID: 35535092 Free PMC article.
-
Hepatoprotection of Probiotics Against Non-Alcoholic Fatty Liver Disease in vivo: A Systematic Review.Front Nutr. 2022 Apr 11;9:844374. doi: 10.3389/fnut.2022.844374. eCollection 2022. Front Nutr. 2022. PMID: 35479741 Free PMC article.
References
-
- WHO. Global status report on alcohol 2004. Geneva: World Health Organization, 2004.
Publication types
LinkOut - more resources
Full Text Sources